Clinical Trial VICCNCPED1225


PHIII Randomized, Double Blind, Placebo Controlled Study to Determine the Safety and Efficacy of Romiplostim in Thrombocytopenic Pediatric Subjects with Immune Thrombocytopenia (ITP)

Principal Investigator(s)

Richard Ho


  • Protocol No. VICCNCPED1225
  • Open Date: 05/24/2012
  • Staging: Phase III
  • Age Group: Children
  • Scope: National
  • Objective: To evaluate the efficacy of romiplostim in the treatment of thrombocytopenia in pediatric subjects with ITP as measured by durable platelet response
  • Disease Sites:
  • Therapies: Correlative
  • Drugs: None Specified
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01444417
  • Secondary Protocol No: 20080279



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.